Satralizumab Biosimilar - Research Grade

Human

IL-6R

>1mg/ml

Human IgG2(C131S/R133K/E137G/C219S/H264Q/R351Q/S374A/Q415E/N430A)-Kappa

Tocilizumab Biosimilar - Research Grade (ICH4012), Sarilumab Biosimilar - Research Grade (ICH5107), Levilimab Biosimilar - Research Grade (ICH5639)

https://www.imgt.org/mAb-DB/

ICH3002

P08887

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of satralizumab, a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. It is built around the IL-6R target to reproduce the binding specificity of the originator molecule for use as a research reagent only (RUO); it is not the clinical drug and is not intended for human or veterinary use. The originator is notable as a "recycling" antibody engineered for pH-dependent antigen binding (tight association at neutral plasma pH, release in the acidic endosome) plus FcRn-mediated recycling, extending half-life and IL-6R engagement; the mutation-rich IgG2 constant region on this card is consistent with that engineering. As a research-grade analog it is useful as a positive control and reference standard in IL-6R binding and neutralization assays, for benchmarking anti-IL-6R biosimilars and novel candidates, for characterizing IL-6/IL-6R signaling in cell-based systems, and as a building block for conjugate or assay development. It is supplied unconjugated at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and available in bulk milligram-to-gram quantities for preclinical and in-vitro workflows. Interleukin-6 receptor (IL-6R, encoded by IL6R; UniProt P08887, also called CD126) is the ligand-binding subunit of the IL-6 signaling system. It exists in a membrane-bound form and as a soluble form (sIL-6R) generated by proteolytic shedding or alternative splicing. IL-6 binding to IL-6R does not signal directly; the IL-6/IL-6R complex recruits two copies of the signal-transducing subunit gp130 (IL6ST/CD130), triggering JAK/STAT3, SHP-2/MAPK, and PI3K/AKT signaling. Membrane IL-6R drives classic signaling in cells that express it (hepatocytes, subsets of leukocytes), while sIL-6R enables trans-signaling on gp130-bearing cells lacking membrane IL-6R, broadening IL-6 responses. IL-6 signaling regulates acute-phase responses, B- and T-cell differentiation, Th17 development, and inflammation. Dysregulated IL-6R signaling is implicated in autoimmune and inflammatory disease, motivating IL-6R blockade.

IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, Interleukin-6 receptor subunit alpha

Detects human IL-6R

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Satralizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Satralizumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Satralizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Satralizumab that binds human IL-6R.